Experimental and clinical results with the thrombin inhibitor Argatroban;Experimentelle und klinische befunde mit dem thrombinhemmer Argatroban

Hamostaseologie

Volumn 22, Issue 3, 2002, Pages 137-141

  Breddin, Hans Klaus ^a  

^a Intl Inst Thromb/Vasc Dis eV   (Germany)

Author keywords

Argatroban; Coagulation inhibitor; Heparin induced thrombocytopenia; Thrombin inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; ARGATROBAN; CHONDROITIN SULFATE; DANAPAROID; DERMATAN SULFATE; DIGOXIN; ERYTHROMYCIN; HEPARIN; HIRUDIN; LEPIRUDIN; LIDOCAINE; THROMBIN INHIBITOR;

ANTIBODY PRODUCTION; ANTICOAGULATION; BLOOD CLOTTING TIME; CORONARY ARTERY SURGERY; DOSE RESPONSE; DRUG METABOLISM; HEART INFARCTION; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; PARTIAL THROMBOPLASTIN TIME; REVIEW; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0036375307     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1619547     Document Type: Review

References (55)

1. Simultaneous monitoring of argatroban and its major metabolite using an HPLC method: Potential clinical applications
2. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia
3. Inhibitor binding to thrombin with X-ray crystallographic studies
4. Crystallographic determination of thrombin complexes with small synthetic inhibitors as a starting point for the receptor-based design of anti-thrombotics
5. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: Comparison with heparin and recombinant hirudin
6. On the role of platelet FcγRIIA phenotype in heparin-induced thrombocytopenia
7. Heparin-induced thrombocytopenia
8. Argatroban, a selective, potent thrombin inhibitor
9. Immune endothelial-cell injury in heparin associated thrombocytopenia
10. Combined administration of aspirin and a specific thrombin inhibitor in man
11. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: Incidence, effects on aPTT, and clinical relevance
12. Heparin-induced thrombocytopenia with thromboembolic complications: Meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range
13. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia
14. Heparin-associated thrombocytopenia: Immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharides
15. Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multi-molecular PF-4 heparin complex as the major antigen
16. Recombinant hirudin (lepirudin) proved safe and effective anticoagulation in patients with heparin-induced thrombocytpenia: A prospective study
17. No effect of clot age or thrombolysis on argatroban's inhibition of thrombin
18. Pharmacological aspects of the development of selective synthetic thrombin inhibitors as anticoagulants
19. Argatroban during percutaneous transluminal coronary angioplasty: Results of a dose-verification study
20. A strategy for a rational approach to designing synthetic selective inhibitors
21. Novastan (brand of argatroban): A small-molecule, direct thrombin inhibitor
22. Effect of hepatic function on the pharmacokinetics and pharmacodynamics of argatroban
23. Effect of renal function on the pharmacokinetics and pharmacodynamics of argatroban (a direct thrombin inhibitor)
24. Lack of interaction between argatroban, a direct thrombin inhibitor, and three frequently prescribed medications, acetaminophen, lidocaine and digoxin
25. Local delivery of argatroban using drug delivery device "dispatch" in the prevention of restenosis following coronary angioplasty trial (40-CAT): Result of the prospective randomized pilot study
26. A multicenter, randomized study of argatroban versus heparin as adjunct to TPA in acute myocardial infarction: Myocardial infarction with Novastan and TPA (MINT) trial
27. Pharmacology of argatroban
28. 2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl) sulfonyl]-L-arginyl)]-2-piperidinecarboxylic acid
29. Argatroban, a direct thrombin inhibitor versus heparin during and after percutaneous transluminal coronary angioplasty (PTCA)
30. Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis
31. Anti-coagulation for HIT with spontaneous platelet aggregation in a patient requiring haemodialysis
32. Argatroban anticoagulation during initial and repeat percutaneous coronary intervention in patients with HIT
33. Successful coronary interventions performed with argatroban anticoagulation in patients with heparin-induced thrombocytopenia and thrombosis syndrome
34. Novastan anticoagulation during renal stent implant in a patient with HIT
35. The first report of successful carotid stent implant using argatroban anticoagulation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome
36. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia
37. Einsatz von danaparoid (Orgaran®) zur antikoagulation bei kardiovaskulären operationen
38. Heparin-induced thrombocytopenia (HIT): An overview on 230 patients treated with orgaran (Org 10172)
39. Pharmacological control of blood coagulation by synthetic low-molecular-weight inhibitors of clotting enzymes. A new concept of anticoagulants
40. Pharmacological control of hyperproteolytic states in blood by synthetic inhibitors of serine proteinases
41. Die Isolierung und chemische charakterisierung des Hirudins
42. Effect of synthetic thrombin inhibitor (MD805) as an alternative drug on HIT during hemodialysis
43. Effect of thrombin inhibition on patients with peripheral arterial obstructive disease: A multicenter clinical trial of argatroban
44. Potent inhibition of thrombin by the newly synthesized arginine derivative no. 805. The importance of stereo-structure of its hydrophobic carboxamide portion
45. Thrombin inhibitors. 1. Ester derivatives of Nα-(arylsulfonyl)-arginine
46. Synthetic selective inhibitors of thrombin
47. Interpreting the International Normalized Ratio in individuals receiving argatroban and warfarin
48. The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction
49. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects
50. Pharmacokinetic studies of argatroban (MD-805): Protein binding and blood cell binding
51. Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban
52. Argatroban and alteplase in patients with acute myocardial infarction: The ARGAMI study
53. Coagulation laboratory testing in patients treated with argatroban
54. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia